Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055982 | 1.00 | DRD2 (0.49) | DRD2DRD1KDM1AMAOAMAOB | |
| SCHEMBL2070013 | 1.00 | DRD2 (0.49) | DRD2DRD1KDM1AMAOAMAOB | |
| SCHEMBL7320995 | 0.83 | — | — | |
| SCHEMBL2069258 | 0.81 | DRD2 (0.48) | DRD2DRD1KDM1AMAOAMAOB | |
| SCHEMBL3803961 | 0.81 | DRD2 (0.48) | DRD2DRD1KDM1AMAOAMAOB | |
| SCHEMBL11885856 | 0.81 | DRD2 (0.51) | DRD2DRD1HTR2AHTR2CHTR2B | |
| SCHEMBL5620402 | 0.81 | DRD2 (0.48) | DRD2DRD1KDM1AMAOAMAOB | |
| SCHEMBL15251760 | 0.81 | DRD2 (0.48) | DRD2DRD1KDM1AMAOAMAOB | |
| SCHEMBL13084081 | 0.81 | DRD2 (0.48) | DRD2DRD1KDM1AMAOAMAOB | |
| SCHEMBL29607628 | 0.81 | DRD2 (0.48) | DRD2DRD1KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569499-B2 | Process for making trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine | H. LUNDBECK A/S (DK) | 2013-10-29 | — | — | US | disclosed |
| US-8569499-B2 | Process for making trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine | H. LUNDBECK A/S (DK) | 2013-10-29 | — | — | US | disclosed |
| US-8450324-B2 | Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine | H. LUNBECK A/S (DK) | 2013-05-28 | — | — | US | disclosed |
| EP-1658276-B1 | TRANS-1(6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | LUNDBECK & CO AS H (DK) | 2012-10-10 | — | — | EP | disclosed |
| US-8227607-B2 | Processes for 4-((1R,35)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a salt thereof | H. LUNDBECK A/S (DK) | 2012-07-24 | — | — | US | disclosed |
| US-8227607-B2 | Processes for 4-((1R,35)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a salt thereof | H. LUNDBECK A/S (DK) | 2012-07-24 | — | — | US | disclosed |
| US-8076342-B2 | Malonate salt of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same | H. LUNDBECK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| US-8076342-B2 | Malonate salt of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same | H. LUNDBECK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| EP-1853576-B1 | CRYSTALLINE BASE OF TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | LUNDBECK & CO AS H (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20110053957-A1 | MALONATE SALT OF 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-03-03 | — | — | US | disclosed |
| US-7767683-B2 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | H. LUNDBECK A/S (DK) | 2010-08-03 | — | — | US | disclosed |
| US-7767683-B2 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | H. LUNDBECK A/S (DK) | 2010-08-03 | — | — | US | disclosed |
| US-20100105699-A1 | CRYSTALLINE BASE OF TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | H. LUNDBECK A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100069676-A1 | PROCESS FOR MAKING TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | US | disclosed |
| US-20100069676-A1 | PROCESS FOR MAKING TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | US | disclosed |
| US-7648991-B2 | Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine | H. LUNDBECK A/S (DK) | 2010-01-19 | — | — | US | disclosed |
| US-20080269248-A1 | Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine | H. LUNDBECK A/S (DK) | 2008-10-30 | — | — | US | disclosed |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | H. LUNDBECK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | H. LUNDBECK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| WO-2005016900-A1 | SUCCINATE AND MALONATE SALT OF TRANS-4-(IR,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND THE USE AS A MEDICAMENT | H. LUNDBECK A/S (DK) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069676-A1 | PROCESS FOR MAKING TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | CYP4Z1, CYP4F3, CYP1A1 | DRD2 472/4885DRD1 301/4885KDM1A 379/4885 |
| US-20100105699-A1 | CRYSTALLINE BASE OF TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | GRIN3A, GRIN2C, ADH1C | DRD2 24/4885DRD1 33/4885KDM1A 3183/4885 |
| US-20080269248-A1 | Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine | MDH2, MDH1, SLC25A11 | DRD2 1083/4885DRD1 664/4885KDM1A 2333/4885 |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | ADH1A, ADH1C, ADH5 | DRD2 10/4885DRD1 14/4885KDM1A 580/4885 |
| US-20110053957-A1 | MALONATE SALT OF 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND USES OF SAME | MAL2, ME1, SYNJ1 | DRD2 462/4885DRD1 489/4885KDM1A 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.